|
Orthologous residues
|
|
CREB (human): S133‑p, CREB iso2 (human): S119‑p, CREB (mouse): S133‑p, CREB (rat): S133‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
myocyte-heart
|
|
Cellular systems studied:
primary cells
|
|
Species studied:
rat
|
|
Comments:
rat MSK1 curated as human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
phenylephrine
|
|
|
|
increase
|
|
|
prazosin
|
phenylephrine
|
|
|
inhibit treatment-induced increase
|
|
|
propranolol
|
phenylephrine
|
|
|
inhibit treatment-induced increase
|
|
|
prazosin, propranolol
|
phenylephrine
|
|
|
inhibit treatment-induced increase
|
|
|
Ro31-8220
|
phenylephrine
|
|
|
inhibit treatment-induced increase
|
|
|
H-89
|
phenylephrine
|
|
|
inhibit treatment-induced increase
|
|
|
SB203580
|
phenylephrine
|
|
|
inhibit treatment-induced increase
|
|
|
8-Rp-cAMP
|
phenylephrine
|
|
|
inhibit treatment-induced increase
|
|
|
forskolin
|
phenylephrine
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
transcription, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
CBP (rat)
|
|
Induces
|
molecular association, regulation
|
transcription, altered
|
co-immunoprecipitation
|
|
